A phase 1b/2 study of JK06, a 5T4-targeted antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer.Omar Saavedra, Nuria Kotecki, V. Boni et al.|Journal of Clinical Oncology|2026Cited by 0